Oculis announced that its Phase 3 DIAMOND trials for OCS-01 eye drops in diabetic macular edema did not meet the primary endpoint of improved visual acuity after 52 weeks. However, the treatment showed significant and lasting reduction in retinal thickness, a secondary measure. The drug was well tolerated with no unexpected side effects. Oculis will not pursue FDA approval for OCS-01 for this condition but will focus on other drug candidates, including Privosegtor for optic nerve disorders and Licaminlimab for dry eye disease. The company maintains strong financial health with cash to fund operations through late 2029.
Allied Gold Corporation announced that Zijin Gold has received approval under the Investment Canada Act for its proposed acquisition of Allied Gold. This approval completes the Canadian regulatory process for the transaction. The deal has also cleare...
Kentucky First Federal Bancorp announced a special board meeting on July 28, 2026, to consider resuming quarterly dividends on its common stock, potentially up to $0.10 per share. The company has suspended dividends since November 2023, and no final ...
Universal Music Group's Board of Directors unanimously rejected an unsolicited buyout proposal from Pershing Square Capital Management, stating it undervalues the company and won't create superior value. The Board, supported by shareholders, highligh...
Cuprina Holdings completed a reverse stock split on May 27, 2026, aiming to meet Nasdaq's minimum $1.00 bid price requirement after failing to regain compliance. The company requested a hearing with the Nasdaq Hearings Panel to appeal a delisting det...
Kun Peng International Ltd. will implement a 1-for-10 reverse stock split of its common stock effective June 2, 2026, reducing outstanding shares from 400 million to about 40 million. The company also amended its Articles of Incorporation to reduce a...
